Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab in Infants with XLH
NCT04188964Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Feb 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of burosumab in X-linked hypophosphatemia (XLH), sponsored by Kyowa Kirin. Started Feb 2020; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT04188964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188964.